Tarsus Pharmaceuticals, Inc. TARS Lease Liability Payments - Remainder of Fiscal Year
Lease Liability Payments - Remainder of Fiscal Year at other companies
Other financials
Where this comes from
Reported directly by Tarsus Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths.
The official record: Tarsus Pharmaceuticals, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about Tarsus Pharmaceuticals, Inc.'s lease liability payments - remainder of fiscal year.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Tarsus Pharmaceuticals, Inc.'s lease liability payments - remainder of fiscal year?
- Tarsus Pharmaceuticals, Inc. (TARS) reported lease liability payments - remainder of fiscal year of $2.63M in Q1 2026.
- What is the long-term trend for Tarsus Pharmaceuticals, Inc.'s lease liability payments - remainder of fiscal year?
- Over 5 years (2020 to 2025), Tarsus Pharmaceuticals, Inc.'s lease liability payments - remainder of fiscal year has grown at a 42.1% compound annual growth rate (CAGR), from $349K to $2.02M.
- What does lease liability payments - remainder of fiscal year mean?
- The contractual cash obligations for operating and finance leases due within the remaining months of the current fiscal year. This provides a short-term view of the company's fixed lease commitments. It is a critical component for assessing near-term liquidity and cash flow requirements.